Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
McGill University
$120,000.00
The Effect of CD271 on Anti-Tumour T cell Function
EF 2025-26
Résumé
Cancer is a leading cause of mortality in Canada, with approximately 22% of Canadians expected to die because of the disease. A major challenge in fighting cancer is maintaining an effective immune response against the tumour. T cells are important players in the anti-tumour immune response. T cells are an extremely powerful subset of immune cells that can identify and kill cancer cells. T cells, however, can also be dangerous, attacking healthy cells and causing autoimmune diseases if their function is not well controlled. Thus, the body has mechanisms in place to ensure that T cells can be turned off when their killing activity is no longer required. One such mechanism involves immune checkpoint molecules. These molecules act as an off switch and negatively regulate T cell function. However, cancer cells take advantage of these molecular stop signs as a means of turning off T cells that would otherwise attack the tumour. In recent years, immune checkpoint inhibitors, which prevent T cells from receiving these stop signals, have revolutionized cancer treatment by restoring anti-tumour T cell activity. However, these therapies do not work for all patients, highlighting the need to identify new targets to reinvigorate the anti-tumour immune response. Our lab has identified a novel immune checkpoint molecule, named CD271, that regulates T cell function. Our preliminary findings suggest that CD271 prevents T cells from becoming activated. My project seeks to understand whether this novel stop signal prevents T cells from effectively killing tumour cells, and if, by blocking its function, we can reinvigorate T cell killing and reduce tumour growth. This research will guide the development of new cancer treatments that enhance existing immunotherapies and expand their application to a wider number of patients and cancer types.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
560201
Name
LaFrancois Ryan J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
The Effect of CD271 on Anti-Tumour T cell Function
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Immunotherapy; Murine Cancer Models; T Cell Checkpoints
Abstract
Cancer is a leading cause of mortality in Canada, with approximately 22% of Canadians expected to die because of the disease. A major challenge in fighting cancer is maintaining an effective immune response against the tumour. T cells are important players in the anti-tumour immune response. T cells are an extremely powerful subset of immune cells that can identify and kill cancer cells. T cells, however, can also be dangerous, attacking healthy cells and causing autoimmune diseases if their function is not well controlled. Thus, the body has mechanisms in place to ensure that T cells can be turned off when their killing activity is no longer required. One such mechanism involves immune checkpoint molecules. These molecules act as an off switch and negatively regulate T cell function. However, cancer cells take advantage of these molecular stop signs as a means of turning off T cells that would otherwise attack the tumour. In recent years, immune checkpoint inhibitors, which prevent T cells from receiving these stop signals, have revolutionized cancer treatment by restoring anti-tumour T cell activity. However, these therapies do not work for all patients, highlighting the need to identify new targets to reinvigorate the anti-tumour immune response. Our lab has identified a novel immune checkpoint molecule, named CD271, that regulates T cell function. Our preliminary findings suggest that CD271 prevents T cells from becoming activated. My project seeks to understand whether this novel stop signal prevents T cells from effectively killing tumour cells, and if, by blocking its function, we can reinvigorate T cell killing and reduce tumour growth. This research will guide the development of new cancer treatments that enhance existing immunotherapies and expand their application to a wider number of patients and cancer types.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
LaFrancois, Ryan J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~